| 1 | | | (DESTINY-BTC01) A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer |
| • Biliary Tract Cancer | AstraZeneca | (OneR Study)
• Kyung, Sungwon | D781PC00001 | NCT06467357 |
| 2 | | | (EmpowHER-303) A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment |
| • Breast Cancer (HER2+) | Jazz Pharmaceuticals | (OneR Study)
• Seneviratne, Lasika | JZP598-303 | NCT06435429 |
| 3 | | | (BRIA-ABC) Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer. |
| • Breast Cancer (HER2+)
• Breast Cancer (HR+ / HER2-)
• Triple Negative Breast Cancer (TNBC) | BriaCell Therapeutics Corp. | • Seneviratne, Lasika | BC-IMT-04 | NCT06072612 |
| 4 | | | (CAPItello-292) A Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer |
| • Breast Cancer (HR+ / HER2-) | AstraZeneca | (OneR Study)
• Seneviratne, Lasika | D361DC00001 | NCT04862663 |
| 5 | | | An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator's Choice of Therapy in Adult Participants With Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy |
| • Breast Cancer (HR+ / HER2-) | Pfizer | • Seneviratne, Lasika | C4551002 | NCT07062965 |
| 6 | | | A Phase 1b/2, Open-Label, Multicohort Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer |
| • Breast Cancer (HR+ / HER2-) | Pfizer | • Seneviratne, Lasika | C5731006 | NCT06966453 |
| 7 | | | (pionERA Breast Cancer) A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy |
| • Breast Cancer (HR+ / HER2-) | Genentech (a member of the Roche Group) | • Seneviratne, Lasika | CO44657 | NCT06065748 |
| 8 | | | (HERTHENA-Breast04) An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer |
| • Breast Cancer (HR+ / HER2-) | Merck & Co. | • Seneviratne, Lasika | MK-1022-016 | NCT07060807 |
| 9 | | | (ALISCA) A Phase 2 Study of Alisertib in Combination With Endocrine Therapy in Patients With HR+, HER2-negative Recurrent or Metastatic Breast Cancer |
| • Breast Cancer (HR+ / HER2-) | Puma Biotechnology | • Seneviratne, Lasika | PUMA-ALI-1201 | NCT06369285 |
| 10 | | | (Cambria-2) A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease |
| • Breast Cancer (HR+ / HER2-) | AstraZeneca | • Jhangiani, Haresh
• Seneviratne, Lasika | D8535C00001 | NCT05952557 |
| 11 | | | Phase 1b/2a Study of GNS561 in Combination With Trametinib in Advanced KRAS Mutated Cholangiocarcinoma |
| • Cholangiocarcinoma (Bile Duct Cancer) | Genfit | • Kyung, Sungwon | GNS561-222-1 | NCT05874414 |
| 12 | | | (OrigAMI-3) A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy |
| • Colorectal Cancer (CRC) | Janssen Research & Development (a Johnson & Johnson company) | (OneR Study)
• Lee, Eric | 61186372COR3002 | NCT06750094 |
| 13 | | | (OrigAMI-2) A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer |
| • Colorectal Cancer (CRC) | Janssen Research & Development (a Johnson & Johnson company) | (OneR Study)
• Lee, Eric | 61186372COR39001 | NCT06662786 |
| 14 | | | (HARMONi-GI3) A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination With FOLFOX Versus Bevacizumab in Combination With FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer |
| • Colorectal Cancer (CRC) | Summit Therapeutics | • Kyung, Sungwon | SMT112-3005 | NCT07228832 |
| 15 | | | (MOUNTAINEER-03) An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer |
| • Colorectal Cancer (CRC) | Seagen (a Pfizer company) | • Kyung, Sungwon
• Lee, Eric | SGNTUC-029 | NCT05253651 |
| 16 | | | (MK-3543-006) A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) Versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia Who Have an Inadequate Response to or Are Intolerant of Hydroxyurea |
| • Essential Thrombocythemia (ET) | Merck & Co. | (OneR Study)
• Kasparian, Saro | MK-3543-006 | NCT06079879 |
| 17 | | | (MK-3543-007) A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK-3543) Versus Hydroxyurea in Cytoreductive Therapy Naïve Essential Thrombocythemia Participants |
| • Essential Thrombocythemia (ET) | Merck & Co. | (OneR Study)
• Kasparian, Saro | MK-3543-007 | NCT06456346 |
| 18 | | | A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination With Trastuzumab and Chemotherapy (XELOX) Versus Trastuzumab and Chemotherapy (XELOX) With or Without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer |
| • Gastric (Stomach) Cancer
• Gastroesophageal Junction Cancer (GEJ) | Shanghai Henlius Biotech | • Kyung, Sungwon | HLX22-GC-301 | NCT06532006 |
| 19 | | | An Open Label, Prospective, Randomized, Parallel Groups, Multicenter Study to Compare the Efficacy and Safety of TachoSil® Versus Surgicel™ Original (Oxidized Regenerated Cellulose) as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery |
| • Hemorrhage | Corza Medical | • Mirhashemi, Ramin | CM-TS01 | NCT06664775 |
| 20 | | | (GLORA) A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
| • Leukemia (CLL - Chronic Lymphocytic Leukemia)
• Lymphoma (SLL - Small Lymphocytic Lymphoma) | Ascentage Pharma Group Corp. | • Tang, Ronald | APG2575CG301 | NCT06104566 |
| 21 | | | (TROPION-Lung15) A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants with EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer whose Disease has Progressed on Prior Osimertinib Treatment |
| • Lung Cancer (NSCLC - Non-Small Cell Lung Cancer) | AstraZeneca | (OneR Study)
• Lee, Eric | D516KC00001 | NCT06417814 |
| 22 | | | (Krascendo 1) A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer |
| • Lung Cancer (NSCLC - Non-Small Cell Lung Cancer) | F. Hoffmann-La Roche | (OneR Study)
• Tang, Ronald | BO45217 | NCT06497556 |
| 23 | | | (ARTEMIDE-Lung02) A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 |
| • Lung Cancer (NSCLC - Non-Small Cell Lung Cancer) | AstraZeneca | (OneR Study)
• Tang, Ronald | D702BC00001 | NCT06692738 |
| 24 | | | (ARTEMIDE-Lung03) A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 |
| • Lung Cancer (NSCLC - Non-Small Cell Lung Cancer) | AstraZeneca | (OneR Study)
• Tang, Ronald | D702FC00001 | NCT06627647 |
| 25 | | | (HARMONIC) Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors |
| • Lung Cancer (NSCLC - Non-Small Cell Lung Cancer) | Lantern Pharma | • Lee, Eric | LTRN300-2LC01-OR21 | NCT05456256 |
| 26 | | | (HARMONi-3) A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer |
| • Lung Cancer (NSCLC - Non-Small Cell Lung Cancer) | Summit Therapeutics | • Lee, Eric | SMT112-3003 | NCT05899608 |
| 27 | | | (HARMONi-7) A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression |
| • Lung Cancer (NSCLC - Non-Small Cell Lung Cancer) | Summit Therapeutics | • Lee, Eric | SMT112-3007 | NCT06767514 |
| 28 | | | (COPERNICUS) A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
| • Lung Cancer (NSCLC - Non-Small Cell Lung Cancer) | Janssen Research & Development (a Johnson & Johnson company) | • Tang, Ronald | 61186372NSC2012 | NCT06667076 |
| 29 | | | (TROPION-Lung14) A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer |
| • Lung Cancer (NSCLC - Non-Small Cell Lung Cancer) | AstraZeneca | • Tang, Ronald | D516NC00001 | NCT06350097 |
| 30 | | | (TROPION-Lung10) A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations |
| • Lung Cancer (NSCLC - Non-Small Cell Lung Cancer) | AstraZeneca | • Tang, Ronald | D7632C00001 | NCT06357533 |
| 31 | | | (TROPION-Lung12) A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer Who Are ctDNA-positive or Have High-risk Pathological Features |
| • Lung Cancer (NSCLC - Non-Small Cell Lung Cancer) | AstraZeneca | • Tang, Ronald | D926TC00001 | NCT06564844 |
| 32 | | | (DESTINY-Lung06) A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination With Pembrolizumab Versus Platinum-based Chemotherapy in Combination With Pembrolizumab, as First-line Therapy in Participants With Locally Advanced Unresectable or Metastatic HER2 Overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer |
| • Lung Cancer (NSCLC - Non-Small Cell Lung Cancer) | Daiichi Sankyo | • Tang, Ronald | DS8201-793 | NCT06899126 |
| 33 | | | (EVOKE-SCLC-04) A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC) |
| • Lung Cancer (SCLC - Small Cell Lung Cancer) | Gilead Sciences | • Tang, Ronald | GS-US-600-6165 | NCT06801834 |
| 34 | | | A Phase II, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| • Lymphoma (DLBCL - Diffuse Large B-Cell Lymphoma) | F. Hoffmann-La Roche | (OneR Study)
• Lee, Eric | GO45434 | NCT06806033 |
| 35 | | | (ELEMENT-MDS) A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-Naive Participants Who Are Non-Transfusion Dependent (NTD) |
| • Myelodysplastic Syndromes (MDS) | Bristol Myers Squibb | • Jhangiani, Haresh | CA056-025 | NCT05949684 |
| 36 | | | (IDeate-PanTumor02) A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors |
| • Other Solid Tumors (Basket Trial) | Daiichi Sankyo | • Kyung, Sungwon | DS7300-203 | NCT06330064 |
| 37 | | | Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers |
| • Other Solid Tumors (Basket Trial) | Flatiron Health | • Salimi-Tari, Peyman | FH-PrwS-07-002 | NCT06605404 |
| 38 | | | (rechARge) A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) |
| • Prostate Cancer (mCRPC - Met Castration-Resistant) | Celgene Corporation (a Bristol Myers Squibb company) | (OneR Study)
• Tang, Ronald | CA071-1000 | NCT06764485 |
| 39 | | | (MEVPRO-2) A Phase 3, Randomized, Double Blind, Placebo Controlled Study of PF-06821497 (Mevrometostat) with Enzalutamide in Metastatic Castration Resistant Prostate Cancer |
| • Prostate Cancer (mCRPC - Met Castration-Resistant) | Pfizer | • Tang, Ronald | C2321003 | NCT06629779 |
| 40 | | | (MEVPRO-1) A Phase 3, Randomized, Open-label Study of PF-06821497 (Mevrometostat) in Combination with Enzalutamide Compared with Enzalutamide or Docetaxel in Participants with Metastatic Castration Resistant Prostate Cancer Previously Treated with Abiraterone Acetate |
| • Prostate Cancer (mCRPC - Met Castration-Resistant) | Pfizer | • Tang, Ronald | C2321014 | NCT06551324 |
| 41 | | | (TROPION-Breast05) A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer |
| • Triple Negative Breast Cancer (TNBC) | AstraZeneca | • Seneviratne, Lasika | D7630C00001 | NCT06103864 |
| 42 | | | A Phase 1/2, Open-label Study of Sacituzumab Govitecan Administered at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer |
| • Triple Negative Breast Cancer (TNBC) | Gilead Sciences | • Seneviratne, Lasika | GS-US-576-7321 | NCT06926920 |
| 43 | | | (ASCENT-05) A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy |
| • Triple Negative Breast Cancer (TNBC) | Gilead Sciences | • Jhangiani, Haresh
• Seneviratne, Lasika | GS-US-595-6184 | NCT05633654 |
| 44 | | | A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia |
| • Waldenstrom Macroglobulinemia | BeiGene | • Lee, Eric | BGB-3111-402 | NCT05640102 |